ICCC immucell.com: חוב לטווח קצר להון עצמי

ImmuCell Corporation (ICCC) focuses on creating innovative antibodies for calf protection, where patent protection precludes the emergence of generics. The market dynamics reflected in the price action on GURU.Markets show a value of 0.07. Despite its narrow specialization within the veterinary segment, ImmuCell Corporation (ICCC) maintains a dominant position, which offsets the risks associated with a lack of product portfolio diversification in the agricultural sector.

Production automation of veterinary tests at ImmuCell Corporation (ICCC) requires stable financing, which is reflected in the current ratio of short-term loans to equity. This metric is calculated by dividing the total liabilities maturing within one year by the total equity, allowing investors to assess the risk of balance sheet overload from short-term debt and determine the stability of the company's financial base.